stockrow
Friday 6 November 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
154.46
11.27
+7.87%
Follow BLTE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 274 | 274 | 543 | +40.7% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — | 0.0 pt | ||||||
| EBT | — | — | — | — | (6) | (10) | (13) | (32) | (36) | (78) | (102) | +68.3% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | (6) | (10) | (13) | (32) | (36) | (78) | (78) | +68.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.65) | (1.01) | (0.65) | (1.19) | (1.18) | (2.31) | (2.73) | +28.7% | ||||||
| Cash flow | — | — | — | — | (0.51) | (0.78) | (0.57) | (1.12) | (0.96) | (1.10) | 0.00 | +16.9% | ||||||
| Capex | — | — | — | — | 0.00 | (0.01) | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 | +18.2% | ||||||
| Free cash flow | — | — | — | — | (0.51) | (0.79) | (0.59) | (1.12) | (0.96) | (1.11) | 0.00 | +16.9% | ||||||
| Book value | — | — | — | — | (0.80) | (1.58) | 2.08 | 3.40 | 4.78 | 22.97 | 19.33 | n/m | ||||||
| Shares, m | — | — | — | — | 9 | 10 | 20 | 27 | 31 | 34 | 37 | +30.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (4) | (7) | (11) | (30) | (29) | (37) | (66) | +52.8% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +54.8% | ||||||
| Free cash flow | — | — | — | — | (4) | (8) | (12) | (30) | (29) | (37) | (67) | +52.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 25 | 16 | 41 | 86 | 141 | 484 | 487 | +81.3% | |||||
| Net debt | — | — | — | — | (26) | (17) | (42) | (88) | (145) | (492) | (492) | +80.6% | ||||||
| Shareholders’ equity | — | — | — | — | (7) | (15) | 42 | 90 | 146 | 770 | 777 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (43.85) | (40.40) | (45.54) | (29.29) | (16.64) | (21.60) | (16.6) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (870.38) | (3,719.87) | (18.93) | (9.55) | (18.9) pt | ||||||
| ROE | — | — | — | — | 0.00 | 87.36 | (95.79) | (47.95) | (30.60) | (16.94) | 0.00 | (16.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 12 | 16 | 20 | 25 | 23 | — | +17.7% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Belite Bio, Inc. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals, Inc. | $6.5B | — (loss-making) | — (loss-making) | −40.73% (below 0%: shrinking) | n/m | +299.29% (above 0%: growing) | 98.98% | (38.18%) | Compare |
| ORKA Oruka Therapeutics, Inc. | $6.4B | — (loss-making) | — | — | n/m | −43.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MIRM Mirum Pharmaceuticals, Inc. | $6.1B | — (loss-making) | — (loss-making) | +39.63% (above 0%: growing) | n/m | −114.22% (below 0%: shrinking) | 81.06% | (32.17%) | Compare |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 116× | 88.3× | −31.80% (below 0%: shrinking) | n/m | −268.45% (below 0%: shrinking) | 96.63% | (20.01%) | Compare |
| IMVT Immunovant, Inc. | $5.9B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BLTE Belite Bio, Inc. Sponsored ADR | $5.8B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | |
| CGON CG Oncology, Inc. | $5.7B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| KOD Kodiak Sciences Inc. | $5.7B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.5B | — (loss-making) | 42.2× | +69.57% (above 0%: growing) | n/m | +90.28% (above 0%: growing) | 93.39% | 7.02% | Compare |
| Median of peers | $5.9B | — | — | +39.63% | — | −38.43% | 40.53% | (10.00%) |